Dietary tomato and lycopene impact androgen signaling- and carcinogenesis-related gene expression during early TRAMP prostate carcinogenesis

Chest

Volumn 146, Issue 6, 2014, Pages 1228-1239

  Wan, Lei ^a,b   Tan, Hsueh Li ^a,b   Thomas Ahner, Jennifer M ^a   Pearl, Dennis K ^a,b   Erdman, John W ^c   Moran, Nancy E ^a   Clinton, Steven K ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; AURORA B KINASE; CYCLIN B2; KI 67 ANTIGEN; LYCOPENE; NERVE GROWTH FACTOR RECEPTOR; OSTEOPONTIN; PROBASIN; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SYNAPTOPHYSIN; TESTOSTERONE; TRANSCRIPTION FACTOR E2F; ANTINEOPLASTIC AGENT; CAROTENOID; MESSENGER RNA; TUMOR MARKER; COLONY STIMULATING FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GAP JUNCTION PROTEIN; GAP JUNCTION PROTEIN ALPHA 1; HERMES ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG;

ALDH1A GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AURORA KINASE B GENE; BIRC5 GENE; BODY WEIGHT; CARCINOGENESIS; CCNE2 GENE; CONTROLLED STUDY; CYCLIN B2 GENE; DIETARY INTAKE; FOXM1 GENE; GENE; GENE EXPRESSION; GENOTYPE; HISTOPATHOLOGY; KI 67 GENE; MALE; MOLECULAR PATHOLOGY; MOUSE; NERVE GROWTH FACTOR RECEPTOR GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROBASIN GENE; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RISK REDUCTION; SECRETED PHOSPHOPROTEIN 1 GENE; SIGNAL TRANSDUCTION; STEROID 5ALPHA REDUCTASE 1 GENE; STEROID 5ALPHA REDUCTASE 2 GENE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1 GENE; SYNAPTOPHYSIN GENE; TOMATO; TRANSCRIPTION FACTOR E2F GENE; WILD TYPE; ADENOCARCINOMA; ANIMAL; C57BL MOUSE; CHEMISTRY; DIET; DNA MICROARRAY; DRUG EFFECTS; ENZYME IMMUNOASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TUMOR CELL CULTURE; ANDROGEN METABOLISM; AURKB GENE; CANCER GROWTH; CCNB2 GENE; CELL DIFFERENTIATION; GENETIC ASSOCIATION; MKI67 GENE; PRIORITY JOURNAL; PROSTATE CANCER; WEIGHT REDUCTION;

ADENOCARCINOMA; ANDROGENS; ANIMALS; ANTICARCINOGENIC AGENTS; BIOMARKERS, TUMOR; CARCINOGENESIS; CAROTENOIDS; DIET; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LYCOPERSICON ESCULENTUM; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84919338275     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0182     Document Type: Article

References (46)

1. Clinton SK, Giovannucci E. Diet, nutrition, and prostate cancer. Annu Rev Nutr 1998;18:413-40.
2. Baetke SC, Adriaens ME, Seigneuric R, Evelo CT, Eijssen LM. Molecular pathways involved in prostate carcinogenesis: insights from public microarray datasets. PLoS ONE 2012;7:e49831.
3. Sharifi N, Auchus RJ. Steroid biosynthesis and prostate cancer. Steroids 2012;77:719-26.
4. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007;7:64.
5. Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 2013;73:2718-36.
6. Tan HL, Thomas-Ahner JM, Grainger EM, Wan L, Francis DM, Schwartz SJ, et al. Tomato-based food products for prostate cancer prevention: what have we learned? Cancer Metastasis Rev 2010;29: 553-68.
7. Sharoni Y, Linnewiel-Hermoni K, Zango G, Khanin M, Salman H, Veprik A, et al. The role of lycopene and its derivatives in the regulation of transcription systems: implications for cancer prevention. Am J Clin Nutr 2012;96:1173S-8S.
8. Campbell JK, Stroud CK, Nakamura MT, Lila MA, Erdman JW Jr. Serum testosterone is reduced following short-term phytofluene, lycopene, or tomato powder consumption in F344 rats. J Nutr 2006; 136:2813-9.
9. Herzog A, Siler U, Spitzer V, Seifert N, Denelavas A, Hunziker PB, et al. Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J 2005;19:272-4.
10. Siler U, Barella L, Spitzer V, Schnorr J, Lein M, Goralczyk R, et al. Lycopene and vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model. FASEB J 2004;18: 1019-21.
11. Boileau TW, Liao Z, Kim S, Lemeshow S, Erdman JW Jr, Clinton SK. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst 2003;95:1578-86.
12. Konijeti R, Henning S, Moro A, Sheikh A, Elashoff D, Shapiro A, et al. Chemoprevention of prostate cancer with lycopene in the TRAMP model. Prostate 2010;70:1547-54.
13. Pannellini T, Iezzi M, Liberatore M, Sabatini F, Iacobelli S, Rossi C, et al. A dietary tomato supplement prevents prostate cancer in TRAMP mice. Cancer Prev Res 2010;3:1284-91.
14. Zuniga KE, Clinton SK, Erdman JW Jr. The interactions of dietary tomato powder and soy germ on prostate carcinogenesis in the TRAMP model. Cancer Prev Res 2013;6:548-57.
15. Zu K, Mucci L, Rosner BA, Clinton SK, Loda M, Stampfer MJ, et al. Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst 2014;106: djt430.
16. Eng MH, Charles LG, Ross BD, Chrisp CE, Pienta KJ, Greenberg NM, et al. Early castration reduces prostatic carcinogenesis in transgenic mice. Urology 1999;54:1112-9.
17. Berman-Booty LD, Sargeant AM, Rosol TJ, Rengel RC, Clinton SK, Chen CS, et al. A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice. Toxicol Pathol 2012;40:5-17.
18. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999;2:70-5.
19. Tan HL, Moran NE, Cichon MJ, Riedl KM, Schwartz SJ, Erdman JW Jr, et al. beta-Carotene-9',10'-oxygenase status modulates the impact of dietary tomato and lycopene on hepatic nuclear receptor-, stress-, and metabolism-related gene expression in mice. J Nutr 2014;144:431-9.
20. Zuniga KE, Erdman JW Jr. Combined consumption of soy germ and tomato powders results in altered isoflavone and carotenoid bioavailability in rats. J Agric Food Chem 2011;59:5335-41.
21. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008;26:317-25.
22. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997;57:4687-91.
23. Haram KM, Peltier HJ, Lu B, Bhasin M, Otu HH, Choy B, et al. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy. Prostate 2008;68:1517-30.
24. Kela I, Harmelin A, Waks T, Orr-Urtreger A, Domany E, Eshhar Z. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors. Prostate 2009;69: 1034-44.
25. Fisher G, Yang ZH, Kudahetti S, Moller H, Scardino P, Cuzick J, et al. Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort. Br J Cancer 2013;108:271-7.
26. Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H. Expression of the survivin gene in prostate cancer: correlation with clinico-pathological characteristics, proliferative activity and apoptosis. J Urol 2004;171:1855-60.
27. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
28. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
29. Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer 2014;14:329-41.
30. Huynh HT, Alpert L, Laird DW, Batist G, Chalifour L, Alaoui-Jamali MA. Regulation of the gap junction connexin 43 gene by androgens in the prostate. J Mol Endocrinol 2001;26:1-10.
31. Czyz J, Szpak K, Madeja Z. The role of connexins in prostate cancer promotion and progression. Nat Rev Urol 2012;9:274-82.
32. Moran NE, Erdman JW Jr, Clinton SK. Complex interactions between dietary and genetic factors impact lycopene metabolism and distribution. Arch Biochem Biophys 2013;539:171-80.
33. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55: 219-37.
34. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008;172:236-46.
35. Guate JL, Escaf S, Menendez CL, del Valle M, Vega JA. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment. Urol Int 1997;59:149-53.
36. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1:487-95.
37. Magbanua MJ, Roy R, Sosa EV, Weinberg V, Federman S, Mattie MD, et al. Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation. PLoS ONE 2011;6:e24004.
38. Steers WD. 5alpha-reductase activity in the prostate. Urology 2001; 58:17-24.
39. Qiu X, Yuan Y, Vaishnav A, Tessel MA, Nonn L, van Breemen RB. Effects of lycopene on protein expression in human primary prostatic epithelial cells. Cancer Prev Res 2013;6:419-27.
40. Huang WC, Li X, Liu J, Lin J, Chung LW. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res 2012;10:133-42.
41. Kasai M, Guerrero-Santoro J, Friedman R, Leman ES, Getzenberg RH, DeFranco DB. The Group 3 LIM domain protein paxillin potentiates androgen receptor transactivation in prostate cancer cell lines. Cancer Res 2003;63:4927-35.
42. Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 2004;64:2212-21.
43. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
44. Holmes C, Stanford WL. Concise review: stem cell antigen-1: expression, function, and enigma. Stem Cells 2007;25:1339-47.
45. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011;10:1378-84.
46. Li T, Su Y, Mei YP, Leng QX, Leng BJ, Liu ZQ, et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 2010;90:234-44.